AAPG Stock Forecast & Price Target

Ascentage Pharma Group is supported by two de-risked commercial anchors, olverembatinib and lisaftoclax, that already generate revenue and are expanding through China formulary penetration, NRDL reimbursement, and a 2025 China launch for lisaftoclax, while 2025 revenue reached $82.1M and cash was $353.2M at year-end 2025. Its outlook is further strengthened by seven Phase 3 trials, including POLARIS-1/-2/-3 and the GLORA series, with late-stage data showing clinically meaningful MRD-negative and response rates in hard-to-treat hematologic cancers and a clear path to potential NDAs in 2H27. The Takeda option agreement validates the platform and provides ex-China upside, while worldwide rights to lisaftoclax, favorable patent coverage, and a pipeline extending into APG-3288 add long-term optionality and support sustained growth.

Ascentage Pharma Group is fundamentally pressured by weak near-term commercialization, as 1H26 product sales of $41.6M fell below the $52.2M estimate and slower adoption in China is limiting olverembatinib growth. Its pipeline still lacks clear de-risking because lisaftoclax faces enrollment or regulatory delays, global studies have not clearly differentiated olverembatinib from incumbents, and key readouts such as POLARIS-1, POLARIS-2, and GLORA-4 remain binary. Although $279.4M of cash may support runway through 2027 and NDA filings are targeted for 2H27, regulatory uncertainty, capital intensity, and concentration in the U.S. and Mainland China sustain a cautious fundamental view.